Last reviewed · How we verify

NCT07199270

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

Recruiting now Phase 1 Last updated 30 September 2025
What this trial tests

Phase 1 trial testing GR2303 injection in Health Adult Subjects in 64 participants. Currently enrolling.

Timeline
18 September 2025
Primary endpoint
18 September 2026
16 December 2026

Quick facts

Lead sponsorGenrix (Shanghai) Biopharmaceutical Co., Ltd.
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingquadruple
Primary purposetreatment
Enrollment64
Start date18 September 2025
Primary completion18 September 2026
Estimated completion16 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with Health Adult Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Health Adult Subjects

Currently open trials in the same condition.

Other Genrix (Shanghai) Biopharmaceutical Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07199270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing